Baseline patient and disease characteristics of patients treated with axi-cel
| Characteristic . | V2Vt . | Overall N = 1383 . | ||
|---|---|---|---|---|
| <28 d, n = 697 . | ≥28 to <40 d, n = 533 . | ≥40 d, n = 153 . | ||
| Median age at infusion (range), y | 61.5 (19.6-86.0) | 62.5 (19.6-90.8) | 63.1 (28.2-84.4) | 62.1 (19.6-90.8) |
| ≥65, n (%) | 239 (34) | 217 (41) | 65 (42) | 521 (38) |
| <65, n (%) | 458 (66) | 316 (59) | 88 (58) | 862 (62) |
| Male, n (%) | 455 (65) | 348 (65) | 91 (59) | 894 (65) |
| Female, n (%) | 242 (35) | 185 (35) | 62 (41) | 489 (35) |
| Race, n (%) | ||||
| White | 573 (82) | 428 (80) | 124 (81) | 1125 (81) |
| Black | 28 (4) | 34 (6) | 9 (6) | 71 (5) |
| Asian | 43 (6) | 27 (5) | 9 (6) | 79 (6) |
| Other or unknown | 53 (8) | 44 (8) | 11 (7) | 108 (8) |
| Ethnicity, n (%) | ||||
| Non-Hispanic | 583 (84) | 450 (84) | 128 (84) | 1161 (84) |
| Hispanic or Latino | 76 (11) | 56 (11) | 18 (12) | 150 (11) |
| Unknown | 38 (5) | 27 (5) | 7 (5) | 72 (5) |
| ECOG PS before infusion, n (%) | ||||
| 0-1 | 613 (88) | 460 (86) | 132 (86) | 1205 (87) |
| ≥2 | 35 (5) | 20 (4) | 9 (6) | 64 (5) |
| Unknown | 49 (7) | 53 (10) | 12 (8) | 114 (8) |
| Histologic transformation, n (%) | 202 (29) | 159 (30) | 41 (27) | 402 (29) |
| Double/triple hit, n (%)∗ | 106 (26) | 87 (29) | 18 (20) | 211 (26) |
| Chemoresistant† before infusion, n (%) | 469 (67) | 355 (67) | 101 (66) | 925 (67) |
| >1 extranodal sites at initial diagnosis, n (%)∗ | 164 (27) | 144 (32) | 49 (36) | 357 (30) |
| Disease stage, n (%)∗ | ||||
| I or II | 168 (29) | 89 (21) | 22 (18) | 279 (25) |
| III or IV | 414 (71) | 341 (79) | 101 (82) | 856 (75) |
| HCT-CI score before infusion, n (%) | ||||
| 0 | 243 (35) | 163 (31) | 32 (21) | 438 (32) |
| 1 | 129 (19) | 97 (18) | 32 (21) | 258 (19) |
| 2 | 84 (12) | 71 (13) | 23 (15) | 178 (13) |
| ≥3 | 241 (35) | 202 (38) | 66 (43) | 509 (37) |
| Any comorbidities, n (%)‡ | 479 (69) | 382 (72) | 125 (82) | 986 (71) |
| Disease histology, n (%) | ||||
| DLBCL | 556 (80) | 424 (80) | 128 (84) | 1108 (80) |
| PMBCL | 26 (4) | 13 (2) | 5 (3) | 44 (3) |
| HGBCL§ | 115 (16) | 96 (18) | 20 (13) | 231 (17) |
| Number of prior lines of systemic therapy, n (%)∗,|| | ||||
| 1–2 | 197 (29) | 153 (30) | 26 (18) | 376 (28) |
| ≥3 | 485 (71) | 361 (70) | 118 (82) | 964 (72) |
| Use of bridging therapy, n (%)∗ | 132 (20) | 109 (22) | 65 (46) | 306 (23) |
| Elevated LDH at initial diagnosis, n (%)∗ | 210 (67) | 156 (74) | 43 (75) | 409 (70) |
| Median time from initial diagnosis to infusion (range), mo | 14.1 (1.2-281.9) | 14.5 (1.2-405.8) | 14.6 (2.6-264.3) | 14.3 (1.2-405.8) |
| <12, n (%) | 300 (43) | 217 (41) | 63 (41) | 580 (42) |
| ≥12, n (%) | 397 (57) | 316 (59) | 90 (59) | 803 (58) |
| Year of axi-cel infusion, n (%) | ||||
| ≤2018 | 210 (30) | 155 (29) | 30 (20) | 395 (29) |
| 2019 | 324 (46) | 252 (47) | 69 (45) | 645 (47) |
| 2020 | 163 (23) | 126 (24) | 54 (35) | 343 (25) |
| Characteristic . | V2Vt . | Overall N = 1383 . | ||
|---|---|---|---|---|
| <28 d, n = 697 . | ≥28 to <40 d, n = 533 . | ≥40 d, n = 153 . | ||
| Median age at infusion (range), y | 61.5 (19.6-86.0) | 62.5 (19.6-90.8) | 63.1 (28.2-84.4) | 62.1 (19.6-90.8) |
| ≥65, n (%) | 239 (34) | 217 (41) | 65 (42) | 521 (38) |
| <65, n (%) | 458 (66) | 316 (59) | 88 (58) | 862 (62) |
| Male, n (%) | 455 (65) | 348 (65) | 91 (59) | 894 (65) |
| Female, n (%) | 242 (35) | 185 (35) | 62 (41) | 489 (35) |
| Race, n (%) | ||||
| White | 573 (82) | 428 (80) | 124 (81) | 1125 (81) |
| Black | 28 (4) | 34 (6) | 9 (6) | 71 (5) |
| Asian | 43 (6) | 27 (5) | 9 (6) | 79 (6) |
| Other or unknown | 53 (8) | 44 (8) | 11 (7) | 108 (8) |
| Ethnicity, n (%) | ||||
| Non-Hispanic | 583 (84) | 450 (84) | 128 (84) | 1161 (84) |
| Hispanic or Latino | 76 (11) | 56 (11) | 18 (12) | 150 (11) |
| Unknown | 38 (5) | 27 (5) | 7 (5) | 72 (5) |
| ECOG PS before infusion, n (%) | ||||
| 0-1 | 613 (88) | 460 (86) | 132 (86) | 1205 (87) |
| ≥2 | 35 (5) | 20 (4) | 9 (6) | 64 (5) |
| Unknown | 49 (7) | 53 (10) | 12 (8) | 114 (8) |
| Histologic transformation, n (%) | 202 (29) | 159 (30) | 41 (27) | 402 (29) |
| Double/triple hit, n (%)∗ | 106 (26) | 87 (29) | 18 (20) | 211 (26) |
| Chemoresistant† before infusion, n (%) | 469 (67) | 355 (67) | 101 (66) | 925 (67) |
| >1 extranodal sites at initial diagnosis, n (%)∗ | 164 (27) | 144 (32) | 49 (36) | 357 (30) |
| Disease stage, n (%)∗ | ||||
| I or II | 168 (29) | 89 (21) | 22 (18) | 279 (25) |
| III or IV | 414 (71) | 341 (79) | 101 (82) | 856 (75) |
| HCT-CI score before infusion, n (%) | ||||
| 0 | 243 (35) | 163 (31) | 32 (21) | 438 (32) |
| 1 | 129 (19) | 97 (18) | 32 (21) | 258 (19) |
| 2 | 84 (12) | 71 (13) | 23 (15) | 178 (13) |
| ≥3 | 241 (35) | 202 (38) | 66 (43) | 509 (37) |
| Any comorbidities, n (%)‡ | 479 (69) | 382 (72) | 125 (82) | 986 (71) |
| Disease histology, n (%) | ||||
| DLBCL | 556 (80) | 424 (80) | 128 (84) | 1108 (80) |
| PMBCL | 26 (4) | 13 (2) | 5 (3) | 44 (3) |
| HGBCL§ | 115 (16) | 96 (18) | 20 (13) | 231 (17) |
| Number of prior lines of systemic therapy, n (%)∗,|| | ||||
| 1–2 | 197 (29) | 153 (30) | 26 (18) | 376 (28) |
| ≥3 | 485 (71) | 361 (70) | 118 (82) | 964 (72) |
| Use of bridging therapy, n (%)∗ | 132 (20) | 109 (22) | 65 (46) | 306 (23) |
| Elevated LDH at initial diagnosis, n (%)∗ | 210 (67) | 156 (74) | 43 (75) | 409 (70) |
| Median time from initial diagnosis to infusion (range), mo | 14.1 (1.2-281.9) | 14.5 (1.2-405.8) | 14.6 (2.6-264.3) | 14.3 (1.2-405.8) |
| <12, n (%) | 300 (43) | 217 (41) | 63 (41) | 580 (42) |
| ≥12, n (%) | 397 (57) | 316 (59) | 90 (59) | 803 (58) |
| Year of axi-cel infusion, n (%) | ||||
| ≤2018 | 210 (30) | 155 (29) | 30 (20) | 395 (29) |
| 2019 | 324 (46) | 252 (47) | 69 (45) | 645 (47) |
| 2020 | 163 (23) | 126 (24) | 54 (35) | 343 (25) |
Patients are from the CIBMTR registry PASS Cohort.
DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; HCT, hematopoietic cell transplantation; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; HGBCL, high grade B-cell lymphoma; LDH, lactate dehydrogenase; NOS, not otherwise specified; PD, progressive disease; PMBCL, primary mediastinal large B-cell lymphoma; SD, stable disease.
Percentages were based on nonmissing cases.
Patients with SD or PD after chemotherapy.
Defined based on the HCT-CI and includes pulmonary (moderate/serve), cardiac/cerebrovascular/heart valve disease, hepatic (moderate/severe), renal (moderate severe), obesity, and/or prior malignancy.
Includes patients with HGBCL NOS and HGBCL with MYC and BCL2 and/or BCL6 rearrangements.
Not including prior HCT.